Infinia vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Montevideo Uruguay YC W23 A2A payments infrastructure for LATAM programmatic money movement; $500K G2/Tekton/YC seed at $1-5M revenue selected for Mastercard Start Path competing with Belvo and Kushki for pay-by-bank infrastructure.
About
Infinia is a Montevideo, Uruguay-based account-to-account (A2A) payments infrastructure company — backed by Y Combinator (W23) with $500,000 in funding from G2 Momentum Capital, Tekton Ventures, YC, Decacorn Capital, and Flucas Ventures — providing fintech companies, marketplaces, and enterprises across Latin America with programmatic money movement infrastructure (pay-by-bank, open banking payments, recurring debit) that enables businesses to move money across Latin American markets without the friction, cost, and settlement delays of traditional card-based payment rails. Founded in 2022 by Alejandro Rettig and Ianai Urwicz in Montevideo, Infinia has generated $1-5 million in annual revenue with 12 employees and was selected for the Mastercard Start Path Emerging Fintech program.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.